Generic companies prevail against AstraZeneca in Patent war over anti-diabetic drug Dapagliflozin
The post outlines Appeals filed by AstraZeneca against refusal of interim injunction in nine Patent infringement lawsuits filed at the Delhi High Court to protect their anti-diabetic drug Dapagliflozin. The claim of AstraZeneca is based on Dapagliflozen (hereinafter referred to as ‘DAPA’) used for treatment of people suffering from type -II diabetes mellitus. DAPA it…